BOEHRINGER INGELHEIM
Boehringer Ingelheim ’ s Head of Data Management , Bruno Rizzuti , explains how Big Pharma builds a better world with tech innovation throughout the enterprise
Humanity faces serious challenges in 2022 : climate change threatens the planet ; global health crises have exposed vulnerabilities in society ; communities are being marginalised ; and demographic trends are creating new pressures on healthcare worldwide . To meet these challenges , pioneering familyowned Boehringer Ingelheim is working on breakthrough therapies with the hope of transforming lives .
First established in Germany in 1885 and now one of the top 20 pharmaceutical companies in the world , Boehringer Ingelheim specialises in areas of unmet medical need in three business areas : Human Pharma , Animal Health , and Biopharmaceutical Contract Manufacturing .
Boehringer Ingelheim strives to develop improved therapies , healthcare products and services to ensure we all live in a better world . The company has plans to increase the scope of its social and environmental ambitions , aiming to explore what more can be done to contribute to a sustainable world and a healthier future .
The company attributes its success to scientific innovation , including investments in sustainable healthcare and technology to accelerate industry improvements . Boehringer Ingelheim is currently pursuing more than 390 research collaborations in the
4 boehringer-ingelheim . es